The company
Generate Biomedicines, Inc.
GENB · Nasdaq
We hold no 150-day reading for GENB yet: it needs about 200 sessions of history. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- not in the set
- Weeks in an uptrend
- —
- Industry in uptrend
- 15% -17 in 4 wk
- Insider buys, 12 months
- $300.6M
- Insider sales, 12 months
- $32K
- Officials’ trades on record
- 0
- Institutions holding
- 84 (+33)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 0 of 0 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Frances ArnoldDirector | sold | 1,000at $16.00 | 1 Sep 2026filed 3 Sep 2026 |
| Michael NallyChief Executive Officer | bought | 20,000at $12.00 | 4 Mar 2026filed 6 Mar 2026 |
| Noubar AfeyanDirector, 10% owner | bought | 1,562,500at $16.00 | 2 Mar 2026filed 2 Mar 2026 |
| Noubar AfeyanDirector, 10% owner | bought | 1,562,500at $16.00 | 2 Mar 2026filed 2 Mar 2026 |
| Noubar AfeyanDirector, 10% owner | bought | 1,562,500at $16.00 | 2 Mar 2026filed 2 Mar 2026 |
| Jane L. MendilloDirector | bought | 1,500at $16.00 | 2 Mar 2026filed 2 Mar 2026 |
| Noubar AfeyanDirector, 10% owner | bought | 1,562,500at $16.00 | 2 Mar 2026filed 2 Mar 2026 |
| Noubar AfeyanDirector, 10% owner | bought | 1,562,500at $16.00 | 2 Mar 2026filed 2 Mar 2026 |
| Noubar AfeyanDirector, 10% owner | bought | 1,562,500at $16.00 | 2 Mar 2026filed 2 Mar 2026 |
| Jason SilversPresident & CFO | bought | 500at $16.00 | 2 Mar 2026filed 2 Mar 2026 |
| Jason SilversPresident & CFO | bought | 500at $16.00 | 2 Mar 2026filed 2 Mar 2026 |
| Jason SilversPresident & CFO | bought | 1,000at $16.00 | 2 Mar 2026filed 2 Mar 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| Flagship Pioneering, LLCunchanged · filed 14 Aug 2026 | 62,673,117$1.1B | 00.0% |
| FMR LLCadded · filed 13 Aug 2026 | 5,221,599$88.1M | +1,004,075+23.8% |
| Capital World Investorsadded · filed 12 Aug 2026 | 4,215,632$71.1M | +211,483+5.3% |
| BRAIDWELL LPreduced · filed 14 Aug 2026 | 3,283,844$55.4M | -309,155−8.6% |
| NORGES BANKnew · filed 12 Aug 2026 | 2,094,616$35.3M | +2,094,616 |
| ARCH Venture Management, LLCunchanged · filed 14 Aug 2026 | 1,944,426$32.8M | 00.0% |
| HarbourVest Partners LLCunchanged · filed 14 Aug 2026 | 1,722,210$29.1M | 00.0% |
| BlackRock, Inc.new · filed 7 Aug 2026 | 1,659,966$28.0M | +1,659,966 |
| BAKER BROS. ADVISORS LPunchanged · filed 14 Aug 2026 | 1,423,602$24.0M | 00.0% |
| JPMORGAN CHASE & COnew · filed 12 Aug 2026 | 1,409,649$23.8M | +1,409,649 |
News
Everyone who traded it
Same industry
No other stock in its industry this week.
Government contracts
No federal award is tied to it.
From its SEC filings
No ratio computed from its SEC filings yet.
Analyst forecasts
No analyst forecasts yet.